Abbott India Limited
Abbott India Limited (ABBOTINDIA.NS) Stock Competitors & Peer Comparison
See (ABBOTINDIA.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABBOTINDIA.NS | ₹25,780.00 | -0.27% | 547.8B | 36.00 | ₹716.05 | +1.84% |
| CIPLA.NS | ₹1,229.50 | +1.12% | 989B | 21.76 | ₹56.27 | +1.31% |
| CIPLA.BO | ₹1,229.60 | +1.14% | 988.9B | 21.78 | ₹56.20 | +1.31% |
| ABBOTINDIA.BO | ₹25,770.05 | -0.32% | 548.2B | 36.31 | ₹710.49 | +1.84% |
| GLAXO.BO | ₹2,393.25 | +1.63% | 399.8B | 41.92 | ₹56.30 | +2.29% |
| GLAXO.NS | ₹2,394.00 | +1.69% | 399.7B | 39.11 | ₹60.33 | +2.29% |
| GLAND.NS | ₹1,741.90 | +0.78% | 288.2B | 33.74 | ₹51.84 | +1.03% |
| GLAND.BO | ₹1,739.85 | +0.62% | 287.7B | 34.00 | ₹51.36 | +1.03% |
| PFIZER.NS | ₹4,868.60 | +0.68% | 217.3B | 25.42 | ₹186.82 | +3.47% |
| PFIZER.BO | ₹4,865.30 | +0.75% | 217.2B | 25.90 | ₹183.33 | +3.47% |
Stock Comparison
ABBOTINDIA.NS vs CIPLA.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, CIPLA.NS has a market cap of 989B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while CIPLA.NS trades at ₹1,229.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas CIPLA.NS's P/E ratio is 21.76. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to CIPLA.NS's ROE of +0.15%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to CIPLA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check CIPLA.NS's competition here
ABBOTINDIA.NS vs CIPLA.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, CIPLA.BO has a market cap of 988.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while CIPLA.BO trades at ₹1,229.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas CIPLA.BO's P/E ratio is 21.78. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to CIPLA.BO's ROE of +0.15%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to CIPLA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check CIPLA.BO's competition here
ABBOTINDIA.NS vs ABBOTINDIA.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, ABBOTINDIA.BO has a market cap of 548.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while ABBOTINDIA.BO trades at ₹25,770.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas ABBOTINDIA.BO's P/E ratio is 36.31. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, ABBOTINDIA.NS is more volatile compared to ABBOTINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check ABBOTINDIA.BO's competition here
ABBOTINDIA.NS vs GLAXO.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, GLAXO.BO has a market cap of 399.8B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while GLAXO.BO trades at ₹2,393.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas GLAXO.BO's P/E ratio is 41.92. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to GLAXO.BO's ROE of +0.56%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to GLAXO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check GLAXO.BO's competition here
ABBOTINDIA.NS vs GLAXO.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, GLAXO.NS has a market cap of 399.7B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while GLAXO.NS trades at ₹2,394.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas GLAXO.NS's P/E ratio is 39.11. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to GLAXO.NS's ROE of +0.56%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to GLAXO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check GLAXO.NS's competition here
ABBOTINDIA.NS vs GLAND.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, GLAND.NS has a market cap of 288.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while GLAND.NS trades at ₹1,741.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas GLAND.NS's P/E ratio is 33.74. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to GLAND.NS's ROE of +0.09%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to GLAND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check GLAND.NS's competition here
ABBOTINDIA.NS vs GLAND.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, GLAND.BO has a market cap of 287.7B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while GLAND.BO trades at ₹1,739.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas GLAND.BO's P/E ratio is 34.00. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to GLAND.BO's ROE of +0.09%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to GLAND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check GLAND.BO's competition here
ABBOTINDIA.NS vs PFIZER.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, PFIZER.NS has a market cap of 217.3B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while PFIZER.NS trades at ₹4,868.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas PFIZER.NS's P/E ratio is 25.42. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PFIZER.NS's ROE of +0.21%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to PFIZER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PFIZER.NS's competition here
ABBOTINDIA.NS vs PFIZER.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, PFIZER.BO has a market cap of 217.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while PFIZER.BO trades at ₹4,865.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas PFIZER.BO's P/E ratio is 25.90. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to PFIZER.BO's ROE of +0.21%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to PFIZER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check PFIZER.BO's competition here
ABBOTINDIA.NS vs SANOFICONR.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, SANOFICONR.NS has a market cap of 105.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while SANOFICONR.NS trades at ₹4,619.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas SANOFICONR.NS's P/E ratio is 43.78. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SANOFICONR.NS's ROE of +0.79%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SANOFICONR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SANOFICONR.NS's competition here
ABBOTINDIA.NS vs SANOFI.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, SANOFI.BO has a market cap of 79.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while SANOFI.BO trades at ₹3,493.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas SANOFI.BO's P/E ratio is 24.43. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SANOFI.BO's ROE of +0.37%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SANOFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SANOFI.BO's competition here
ABBOTINDIA.NS vs SANOFI.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, SANOFI.NS has a market cap of 79.8B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while SANOFI.NS trades at ₹3,491.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas SANOFI.NS's P/E ratio is 24.41. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SANOFI.NS's ROE of +0.37%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SANOFI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SANOFI.NS's competition here
ABBOTINDIA.NS vs MARKSANS.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, MARKSANS.BO has a market cap of 79.3B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while MARKSANS.BO trades at ₹178.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas MARKSANS.BO's P/E ratio is 22.56. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to MARKSANS.BO's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to MARKSANS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check MARKSANS.BO's competition here
ABBOTINDIA.NS vs MARKSANS.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, MARKSANS.NS has a market cap of 79.3B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while MARKSANS.NS trades at ₹178.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas MARKSANS.NS's P/E ratio is 22.01. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to MARKSANS.NS's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to MARKSANS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check MARKSANS.NS's competition here
ABBOTINDIA.NS vs SMSPHARMA.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, SMSPHARMA.BO has a market cap of 38.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while SMSPHARMA.BO trades at ₹419.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas SMSPHARMA.BO's P/E ratio is 41.38. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SMSPHARMA.BO's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SMSPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SMSPHARMA.BO's competition here
ABBOTINDIA.NS vs SMSPHARMA.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, SMSPHARMA.NS has a market cap of 38.9B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while SMSPHARMA.NS trades at ₹418.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas SMSPHARMA.NS's P/E ratio is 41.42. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SMSPHARMA.NS's ROE of +0.14%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SMSPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SMSPHARMA.NS's competition here
ABBOTINDIA.NS vs SENORES.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, SENORES.NS has a market cap of 37.1B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while SENORES.NS trades at ₹821.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas SENORES.NS's P/E ratio is 31.31. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to SENORES.NS's ROE of +0.13%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to SENORES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check SENORES.NS's competition here
ABBOTINDIA.NS vs NGLFINE.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, NGLFINE.BO has a market cap of 14.6B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while NGLFINE.BO trades at ₹2,329.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas NGLFINE.BO's P/E ratio is 41.41. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to NGLFINE.BO's ROE of +0.12%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to NGLFINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check NGLFINE.BO's competition here
ABBOTINDIA.NS vs NGLFINE.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, NGLFINE.NS has a market cap of 14.6B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while NGLFINE.NS trades at ₹2,331.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas NGLFINE.NS's P/E ratio is 41.33. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to NGLFINE.NS's ROE of +0.12%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to NGLFINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check NGLFINE.NS's competition here
ABBOTINDIA.NS vs TTKHLTCARE.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, TTKHLTCARE.NS has a market cap of 12.2B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while TTKHLTCARE.NS trades at ₹886.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas TTKHLTCARE.NS's P/E ratio is 20.28. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to TTKHLTCARE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check TTKHLTCARE.NS's competition here
ABBOTINDIA.NS vs KOPRAN.BO Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, KOPRAN.BO has a market cap of 7.5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while KOPRAN.BO trades at ₹157.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas KOPRAN.BO's P/E ratio is 45.67. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to KOPRAN.BO's ROE of +0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to KOPRAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check KOPRAN.BO's competition here
ABBOTINDIA.NS vs KOPRAN.NS Comparison April 2026
ABBOTINDIA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABBOTINDIA.NS stands at 547.8B. In comparison, KOPRAN.NS has a market cap of 7.5B. Regarding current trading prices, ABBOTINDIA.NS is priced at ₹25,780.00, while KOPRAN.NS trades at ₹157.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABBOTINDIA.NS currently has a P/E ratio of 36.00, whereas KOPRAN.NS's P/E ratio is 45.62. In terms of profitability, ABBOTINDIA.NS's ROE is +0.38%, compared to KOPRAN.NS's ROE of +0.03%. Regarding short-term risk, ABBOTINDIA.NS is less volatile compared to KOPRAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for ABBOTINDIA.NS.Check KOPRAN.NS's competition here